Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ExoFlo in moderate-to-severe ARDS
NCT05354141Phase 3Recruiting
- Sponsor
- Direct Biologics
- Start
- Jul 2022
- Primary completion
- Nov 2027
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of bone marrow mesenchymal stem cell derived extracellular vesicles in acute respiratory distress syndrome (ARDS), sponsored by Direct Biologics. Started Jul 2022; status: recruiting.
02
Drugs
bone marrow mesenchymal stem cell derived extracellular vesicles
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT05354141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05354141.